FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385669137> ?p ?o ?g. }

• W4385669137 endingPage "S112" @default.
• W4385669137 startingPage "S111" @default.
• W4385669137 abstract "Introduction In recent years, cannabis use among PTSD patients has become more common than ever. However, data available today regarding the effectiveness and safety of medical cannabis in PTSD treatment is limited, based on cross sectional studies, self-report surveys and a few clinical studies with small sample size. Objectives To characterize patterns of use and adverse effects over time in patients with PTSD using medical cannabis in real life setting. Methods Data were acquired from the Israeli national database of all patients licensed to use medical cannabis from January 2014 to December 2021. A license for medical cannabis is given to patients with PTSD of at least moderate intensity after treatment failure of at least two drugs and two psychological interventions. Comparative statistics were used to evaluate patterns of use and adverse effects. Results 12,977 patients were licensed to use medical cannabis in the study period for PTSD (8.2% of all users; 70% men) during the above-mentioned time period. PTSD was the 3 rd most common indication after chronic pain and symptoms related to oncological disease and chemotherapy treatment. Over time, the relative increase in use of medical cannabis among PTSD patients was higher than that found in non-PTSD patients. In 2021 36.2% of all PTSD patients using medical cannabis had their license issued that year compared to 28.1% of all non-PTSD patients. PTSD patients were significantly younger compared to non-PTSD patients (40.9 years vs. 52.9 years). PTSD patients consume slightly higher monthly amount at the beginning of treatment compared to non-PTSD patients (32.1gr vs. 30.6gr) with higher Tetrahydrocannabinol (THC) concentration (15.2% vs. 12.9%) and lower Cannabidiol (CBD) concentration (4.7% vs. 6.0%). Over two years of use, amount, and composition of cannabis among the two groups were comparable and showed an increase in total amount and THC concentration, reaching the maximal available THC concentration of 20%. Data regarding adverse effects were available for 6,242 PTSD patients (48.1%) and 39,497 non-PTSD patients (26.6%). PTSD patients reported more physical adverse effects (RR 1.45 [95%CI 1.34-1.56]), anxiety (RR 1.47 [95%CI 1.13-1.92]), and derealization (RR 3.44 [95%CI 2.42-4.89]). Conclusions PTSD is one of the leading indications for medical cannabis use in Israel, despite scarcity in good quality data supporting its effectiveness and safety. The increased risk of mental adverse effects among PTSD patients emphasizes the need for cautious use in cannabis in this population. Expanding the knowledge regarding patterns of use and risks in medical cannabis use among PTSD patients is important for understanding the role of cannabis in PTSD treatment and to ensure an effective and safe treatment. Disclosure of Interest None Declared" @default.
• W4385669137 created "2023-08-09" @default.
• W4385669137 creator A5007772248 @default.
• W4385669137 creator A5027689918 @default.
• W4385669137 creator A5066536962 @default.
• W4385669137 creator A5074088108 @default.
• W4385669137 creator A5078650252 @default.
• W4385669137 date "2023-03-01" @default.
• W4385669137 modified "2023-09-22" @default.
• W4385669137 title "Medical cannabis use among patients with Post-Traumatic Stress Disorder (PTSD): A nationwide database study" @default.
• W4385669137 doi "https://doi.org/10.1192/j.eurpsy.2023.306" @default.
• W4385669137 hasPublicationYear "2023" @default.
• W4385669137 type Work @default.
• W4385669137 citedByCount "0" @default.
• W4385669137 crossrefType "journal-article" @default.
• W4385669137 hasAuthorship W4385669137A5007772248 @default.
• W4385669137 hasAuthorship W4385669137A5027689918 @default.
• W4385669137 hasAuthorship W4385669137A5066536962 @default.
• W4385669137 hasAuthorship W4385669137A5074088108 @default.
• W4385669137 hasAuthorship W4385669137A5078650252 @default.
• W4385669137 hasBestOaLocation W43856691371 @default.
• W4385669137 hasConcept C118552586 @default.
• W4385669137 hasConcept C126322002 @default.
• W4385669137 hasConcept C195910791 @default.
• W4385669137 hasConcept C197934379 @default.
• W4385669137 hasConcept C27415008 @default.
• W4385669137 hasConcept C2777056318 @default.
• W4385669137 hasConcept C3019398298 @default.
• W4385669137 hasConcept C71924100 @default.
• W4385669137 hasConceptScore W4385669137C118552586 @default.
• W4385669137 hasConceptScore W4385669137C126322002 @default.
• W4385669137 hasConceptScore W4385669137C195910791 @default.
• W4385669137 hasConceptScore W4385669137C197934379 @default.
• W4385669137 hasConceptScore W4385669137C27415008 @default.
• W4385669137 hasConceptScore W4385669137C2777056318 @default.
• W4385669137 hasConceptScore W4385669137C3019398298 @default.
• W4385669137 hasConceptScore W4385669137C71924100 @default.
• W4385669137 hasIssue "S1" @default.
• W4385669137 hasLocation W43856691371 @default.
• W4385669137 hasOpenAccess W4385669137 @default.
• W4385669137 hasPrimaryLocation W43856691371 @default.
• W4385669137 hasRelatedWork W18043055 @default.
• W4385669137 hasRelatedWork W2733685407 @default.
• W4385669137 hasRelatedWork W2981985414 @default.
• W4385669137 hasRelatedWork W3048010670 @default.
• W4385669137 hasRelatedWork W3087000546 @default.
• W4385669137 hasRelatedWork W3169839459 @default.
• W4385669137 hasRelatedWork W4223477543 @default.
• W4385669137 hasRelatedWork W4292854942 @default.
• W4385669137 hasRelatedWork W4294200776 @default.
• W4385669137 hasRelatedWork W4380304139 @default.
• W4385669137 hasVolume "66" @default.
• W4385669137 isParatext "false" @default.
• W4385669137 isRetracted "false" @default.
• W4385669137 workType "article" @default.